Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
BioNTech reported better-than-expected third-quarter 2024 results, with revenue of €1.37 billion, up 40.38% year-over-year, driven by solid sales of its variant-adapted COVID-19 vaccines. Earnings per share were €0.89, beating expectations by €2.56. Despite lowering its full-year revenue outlook due to factors such as COVID-19 uptake, price levels, inventory write-downs, and Pfizer charges, BioNTech shares rose 2.44% in premarket trading.
Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast https://t.co/JLUQhcsEhl https://t.co/Pqh67bSpAH
Solaris Energy Infrastructure Announces Third Quarter 2024 Results, New Power Solutions Contracts, and Continued Shareholder Returns for Fourth Quarter 2024 https://t.co/j6P73SRgSj https://t.co/lt8r3sSuJr
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics https://t.co/huwgydfoal https://t.co/C6n44G3IK9